Natural versus vaccine immunity

Post infection natural immunity, debate and implications for mandatory vaccination

US as of 11th December 2020

US, Natural infection, Feb 2020 to May 2021

0 – 17 26.8 / 73 37%

18 – 49 60.5 / 138 44%

50 – 64 20.4 / 62 32%

65+ 12.3 / 54 23%

Total 120.3/ 328 37%

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

N = 254 blood samples post infection

N = 51 long term follow up

Antibodies against SARSCoV-

2 spike and receptor binding domain

(RBD) declined moderately over 8 months

Memory B cells against SARS-CoV-2 spike

increased between 1 month and 8 months

after infection.

Proportion of subjects positive for CD4+ T cells (92%) remained high at 6 to 8 months after infection.

The different types of immunememory each had distinct kinetics, resulting in complex interrelationships over time

CONCLUSION

Substantial immune memory is generated after COVID-19

About 95% of subjects retained immune memory at ~6 months after infection

Circulating antibody titers were not predictive of T cell memory

CDC

Still recommends a full vaccination dose for all

the immune response from vaccination is more predictable

antibody responses after infection vary widely by individual

June, Peter Marks, Food and Drug Administration’s Center for Biologics Evaluation and Research

We do know that the immunity after vaccination is better than the immunity after natural infection

generally the immunity after natural infection tends to wane after about 90 days

It appears from the literature that natural infection provides immunity,

but that immunity is seemingly not as strong and may not be as long lasting as that provided by the vaccine

UK covid pass guidelines

proof of natural immunity shown by a positive PCR test result for COVID-19, lasting for 180 days after the date of the positive test

Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel

Vaccination was highly effective

Estimated efficacy for documented infection of 92·8%

Hospitalization 94·2%

Severe illness 94·4%

Death 93·7%

Protection from prior SARS-CoV-2 infection

Estimated efficacy for documented infection of 94·8%

Hospitalization 94·1%

Severe illness 96·4%

Ministry of Health during summer surge

Between 5 July and 3 August

(over half a million infected but unvaccinated)

Just 1% of weekly new cases were in people who had previously had covid-19

Dvir Aran, biomedical data, Technion–Israel Institute of Technology

these numbers look very low

the data suggest that the recovered have better protection than people who were vaccinated

Systemic side-effects were more common in people previously infected

Large UK study

1·6 times after the first dose of ChAdOx1 nCoV-19

2·9 times after the first dose of BNT162b2

56% more likely to experience a severe side effect that required hospital care

Conclusion

Public health strategy versus individualised medicine